Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Advancing IBD Therapy by Sharing New Clinical Insights & Future Directions of Recent Approvals

By | 4 November 2025

Discover the latest clinical data and real-world insights to understand impacts on patient outcomes in Ulcerative Colitis and Crohn’s disease
Learn how recent regulatory approvals are expanding treatment options and improving access for patients with IBD
Explore future directions in IBD care by examining ongoing research, pipeline developments, and strategies for integrating new therapies into clinical practice